Author

J. Schwaller

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2

Frequent Co-Authors

A. Bruggemans· 1 shared A. Curti· 1 shared A. Gulino· 1 shared A. J. Finch· 1 shared A. M. Magee· 1 shared A. Piva· 1 shared A. Rio-Machin· 1 shared A. S. Wilhelmson· 1 shared

Activity by Year

2022-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 12 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperMicrobiology

A. Bruggemans

Author profile →

4 papers

Recent·Most cited

SCD inhibition eradicates AML displaying high de novo fatty acid desaturation and synergizes with chemotherapy

V. Dembitz, H. Lawson, R. Burt, C. Philippe, S. C. James, S. Atkinson, J. Durko, L. M. Wang, J. Campos, A. M. Magee, K. Woodley, M. J. Austin, A. Rio-Machin, P. Casado-Izquierdo, F. Bewicke-Copley, , P. Gallipoli

SCD inhibition induces AML cell death and synergizes with chemotherapy to prolong survival in murine AML models.

bioRxiv · Aug 2, 2023Cancer Biology

ZEB1 shapes AML immunological niches suppressing CD8 T-cell activity while fostering Th17 cell expansion.

B. Bassani, G. Simonetti, V. Cancila, M. Ciciarello, A. Piva, C. Chiodoni, D. Lecis, A. Gulino, E. Fonzi, L. Botti, P. Portararo, M. Costanza, J. Schwaller, A. Tzankov, M. Ponzoni, , S. Sangaletti

This study shows ZEB1 in AML suppresses CD8 T-cells and promotes Th17 cells, contributing to immune suppression and tumor progression.

bioRxiv · Jul 8, 2023Immunology

TET2 lesions enhance the aggressiveness of CEBPA-mutant AML by rebalancing GATA2 expression

E. Heyes, A. S. Wilhelmson, A. Wenzel, G. Manhart, T. Eder, M. B. Schuster, E. Rzepa, S. Pundhir, T. D'Altri, C. Gentil, M. Meggendorfer, J. Schwaller, T. Haferlach, F. Grebien, B. T. Porse

This study identifies GATA2 as a target of the CEBPA-TET2 mutational axis in AML, showing how TET2 lesions rebalance GATA2 expression and enhance disease aggressiveness.

bioRxiv · Mar 28, 2023Cancer Biology

BET-independent MLV integration is retargeted in vivo and selects distinct genomic elements for lymphomagenesis

I. Nombela, M. Michiels, D. Van Looveren, L. Marcelis, S. el Ashkar, S. Van Belle, A. Bruggemans, T. Tousseyn, J. Schwaller, F. Christ, R. Gijsbers, J. De Rijck, Z. Debyser

This study compares BET-dependent and -independent MLV integration in mice, finding that BET proteins influence integration site selection but not tumorigenesis.

bioRxiv · Feb 23, 2022 · PreprintMicrobiology